Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals.
about
Review of nonalcoholic fatty liver disease in women with polycystic ovary syndromePriorities for transgender medical and healthcare research.Alterations in Lipids and Adipocyte Hormones in Female-to-Male Transsexuals.The Role of Androgens in Normal and Malignant Breast Tissue.Sex steroid actions in male boneSIAMS-ONIG Consensus on hormonal treatment in gender identity disorders.Hormonal management of the female-to-male transgender patient.Effects of long-term exogenous testosterone administration on ovarian morphology, determined by transvaginal (3D) ultrasound in female-to-male transsexuals.Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review.Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons.Cross-sex hormone therapy in transgender persons affects total body weight, body fat and lean body mass: a meta-analysis.Supraphysiological testosterone enanthate administration prevents bone loss and augments bone strength in gonadectomized male and female rats.Relationship between testosterone in serum, saliva and urine during treatment with intramuscular testosterone undecanoate in gender dysphoria and male hypogonadism.High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance.
P2860
Q26828765-51ED730D-4417-4181-BFC1-48FFBA98D183Q30359711-FC2B392A-479E-4836-9174-0BA3CD7BCC46Q34034792-6532BC88-7C94-482D-9F50-D70610470F3EQ34096288-5F0F5908-1186-4622-971C-87B08344E362Q34437537-8848042D-07AD-471D-ADB6-6C6EFA6247A8Q37672115-A777AA49-F6CE-45E5-93AA-C4C28D406D8FQ37871048-DFA7B1E1-8272-4DAE-ABC8-45A3A2AB1387Q38785823-8EDB1ED4-3484-4AE0-9E6B-68B99C55F0F1Q39435553-8491907A-8A38-40EE-8989-95031FC957E1Q39453462-DCA6B98B-6D34-42F4-A61F-3E6DDEF99ED3Q40602937-BF48A2D1-0197-4FD0-B5CB-F68E5B063713Q46379434-DB1C90AF-59CB-4F6D-B31A-53A6ECC1C8F0Q49959483-DA168B5C-81DF-4A4E-9193-89D8E7498FCCQ51011840-2EC0ECB1-45E2-42C1-8E2F-465110832414
P2860
Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Long-term administration of te ...... n female-to-male transsexuals.
@en
Long-term administration of te ...... n female-to-male transsexuals.
@nl
type
label
Long-term administration of te ...... n female-to-male transsexuals.
@en
Long-term administration of te ...... n female-to-male transsexuals.
@nl
prefLabel
Long-term administration of te ...... n female-to-male transsexuals.
@en
Long-term administration of te ...... n female-to-male transsexuals.
@nl
P2093
P356
P1476
Long-term administration of te ...... n female-to-male transsexuals.
@en
P2093
Andreas Mueller
Franklin Kiesewetter
Helge Binder
Ralf Dittrich
P304
P356
10.1210/JC.2007-0746
P407
P577
2007-06-19T00:00:00Z